3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Urinary Bladder Neoplasms
2
Triple Negative Breast Neoplasms
1
Small Cell Lung Carcinoma
1
Recurrence
1
Prostatic Neoplasms
1
Osteosarcoma
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplasms
1
Lymphoma, T-Cell, Peripheral
1
Immunoblastic Lymphadenopathy
1
Carcinoma in Situ
1
Breast Neoplasms
1
Advanced Solid Tumor Cancer
1
Interventions
Bevacizumab
69
atezolizumab
54
lenvatinib
42
durvalumab
42
Nivolumab
38
pembrolizumab
35
tremelimumab
28
Magnetic Resonance Spectroscopy
21
Specimen Handling
19
tislelizumab
18
sintilimab
17
Ipilimumab
15
Sorafenib
14
regorafenib
13
cabozantinib
13
Radiosurgery
13
Radiotherapy
12
apatinib
11
Blood Specimen Collection
11
Immunoglobulin G
10
camrelizumab
9
Immune Checkpoint Inhibitors
9
Disulfides
9
X-Rays
8
Cyclophosphamide
8
donafenib
7
Oxaliplatin
7
Immunotherapy
7
Folfox protocol
7
Fluorouracil
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Carcinoma, Hepatocellular
×
Clinical Trials, Phase II as Topic
×
1 year
×
Clear all
No trials found.